Alexander Erica S, Soulen Michael C
From the Division of Interventional Radiology, University of Pennsylvania, Philadelphia, PA.
Cancer J. 2016 Nov/Dec;22(6):381-386. doi: 10.1097/PPO.0000000000000232.
Patients with noncolorectal hepatic metastases often face limited treatment options and a dismal prognosis. Over the last decade, the advent of targeted immunotherapies has transformed the treatment of certain metastatic cancers, such as sarcoma and melanoma; however, these patients eventually develop resistance. Metastatic sarcoma, melanoma, and breast and neuroendocrine tumors are notoriously treatment resistant once they have metastasized to the liver. For these cancers, minimally invasive transarterial and ablation therapies have emerged as safe, palliative therapies that can provide symptom control and even prolong survival.
非结直肠癌肝转移患者通常面临有限的治疗选择和预后不佳的情况。在过去十年中,靶向免疫疗法的出现改变了某些转移性癌症的治疗方式,如肉瘤和黑色素瘤;然而,这些患者最终会产生耐药性。转移性肉瘤、黑色素瘤、乳腺癌和神经内分泌肿瘤一旦转移到肝脏,就 notoriously 具有治疗抗性。对于这些癌症,微创经动脉和消融疗法已成为安全的姑息性疗法,可提供症状控制甚至延长生存期。